Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Melinda Kedves¹, Fruzsina Kósa ², Péter Takács ², Péter Kunovszki ², Jennifer Lofland ³ and György Nagy ⁴, ¹Hospital of Bács-Kiskun County, Department of Rheumatology, Kecskemét, Bacs-Kiskun, Hungary, ²Janssen, GCSO, Budapest, Budapest, Hungary, ³Janssen Scientific Affairs, LLC, Spring House, PA, ⁴Buda Hospital of the Hospitaller Order of Saint John of God, Department of Rheumatology, Budapest, Budapest, Hungary
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 1606 • 2019 ACR/ARP Annual Meeting
Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Smoking and African- American ethnicity are risk factors for systemic lupus erythematosus (SLE). Smoking has been associated with increased prevalence of SLE, increased disease…
Abstract Number: 1767 • 2019 ACR/ARP Annual Meeting
Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Matteo Cesaroni¹, Loqmane Seridi ¹, Jarrat Jordan ¹, Kristen Sweet ¹, Keying Ma ¹, Carol Franks ¹, Jessica Schreiter ¹, Peter Lipsky ², Ronald van Vollenhoven ³, Bevra Hahn ⁴, Shawn Rose ¹, Frédéric Baribaud ¹, Matthew Loza ¹, Kim Campbell ¹ and George Tsokos ⁵, ¹Janssen Research & Development, LLC, Spring House, PA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴University of California, Los Angeles, CA, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease that causes progressive organ damage. The cytokines type I interferon (IFN-I), IL-12 and IL-23 have…
Abstract Number: 2027 • 2019 ACR/ARP Annual Meeting
Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Teresa Aberle ¹, Cristina Arriens ², Stefania Gallucci ³ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lewis Katz School of Medicine, Temple University, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…
Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Min Kyung Chung ¹, Jin Su Park ², Hyun Sun Lim ², Chan Hee Lee ² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…
Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Naoto Yokogawa¹, Masayuki Hashiguchi ², Yoshiki Nagai ³, Kota Shimada ⁴, Shoji Sugii ¹, Miho Oshima ⁵, Keigo Setoguchi ⁶ and Mikiko Shimizu ⁷, ¹Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, ²Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan, ³Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ⁴Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, ⁵Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan, ⁶Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, ⁷Department of Drug Metabolism and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan
Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…
Abstract Number: 2737 • 2019 ACR/ARP Annual Meeting
HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Barry Garchow¹ and Marianthi Kiriakidou ¹, ¹Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Hypoxia inducible factor 1 is a key transcription factor that regulates the cellular response to oxygen stress. In the adaptive immune system, HIF-1α is…
Abstract Number: 2883 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
April Barnado¹, Lee Wheless ¹, Leslie Crofford ² and Joshua Denny ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria…
Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Miao Jiang¹, Aimee Near ², Barnabas Desta ¹, Xia Wang ¹ and Edward Hammond ¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…
Abstract Number: 682 • 2019 ACR/ARP Annual Meeting
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Victor Pimentel-Quiroz ³, Cristina Reátegui-Sokolova ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Luciana Gil ², Samira García ⁴, Francisco Zevallos ⁴, Cesar Pastor-Asurza ⁴, Zoila Rodríguez-Bellido ², Anca Askanase ⁵, Joan Merrill ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Columbia University, New York, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: Disease activity in systemic lupus erythematosus (SLE) is understood differently by patients and physicians; furthermore, there are no reliable measures for patients to assess…
Abstract Number: 943 • 2019 ACR/ARP Annual Meeting
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Sarfaraz Hasni¹, Sarthak Gupta ², Michael Davis ³, Elaine Poncio ⁴, Yenealem Temesgen-Oyelakin ⁴, Phillip Carlucci ⁴, Xinghao Wang ⁴, Mohammad Naqi ⁴, Martin Playford ⁵, Rishi Goel ⁴, Xiaobai Li ⁶, Ann Biehl ⁴, Isabel Ochoa-Navas ⁴, Zerai Manna ⁴, Yinghui Shi ⁷, Don Thomas ⁸, Jinguo Chen ⁹, Angélique Biancotto ⁹, Richard Apps ⁹, Foo Cheung ⁹, Yuri Kotliarov ⁹, Ashley Babyak ⁶, Katie Stagliano ⁹, John Tsang ⁹, Wanxia Tsai ¹⁰, Laura Vian ¹⁰, Nathalia Gazaniga ⁴, Valentina Giudice ⁴, Stephen Brooks ¹¹, Meggan Mackay ¹², Peter Gregersen ¹³, Betty Diamond ¹⁴, Nehal Mehta ¹⁵, Alan Remaley ⁵, John O'Shea ¹⁶, Massimo Gadina ¹⁰ and Mariana Kaplan ¹⁶, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, ⁵NHLBI/NIH, Bethesda, ⁶Clinical Center/NIH, Bethesda, ⁷Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹NIAID/NIH, Bethesda, ¹⁰Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ¹¹Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹²Feinstein Institute for Medical Research, New York, ¹³Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁴Feinstein Institutes of Medical Research, Manhasset, NY, ¹⁵National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ¹⁶National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda
Background/Purpose: A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of…
Abstract Number: 1103 • 2019 ACR/ARP Annual Meeting
Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US
Yiting Wang¹, Laura Hester ¹, Jennifer Lofland ², Shawn Rose ³, Chetan Karyekar ⁴, Dave Kern ⁵, Margaret Blacketer ¹, Kourtney Davis ¹ and Kimberly Shields-Tuttle ⁶, ¹Janssen Research & Development, LLC, Titusville, ²Janssen Scientific Affairs, LLC, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, Titusville, ⁶Janssen Research & Development, LLC, Spring House
Background/Purpose: One study estimated that between 161,000 and 322,000 people in the US had definite or probable SLE, based on data from the period of…
Abstract Number: 1565 • 2019 ACR/ARP Annual Meeting
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Jagan Sivakumaran¹, Paula Harvey ², Ahmed Omar ³, Murray Urowitz ³, Dafna Gladman ⁴, Nicole Anderson ³, Jiandong Su ³ and Zahi Touma ³, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment…
Abstract Number: 1607 • 2019 ACR/ARP Annual Meeting
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].